Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Stock Chart & Stats
$7.18
-$0.47(-4.69%)
At close: 4:00 PM EST
$7.18
-$0.47(-4.69%)
Day’s Range― - ―
52-Week Range$4.81 - $10.73
Previous Close$9.5
Volume184.55K
Average Volume (3M)657.06K
Market Cap
$1.39M
Enterprise Value$0.00
Total Cash (Recent Filing)$116.53M
Total Debt (Recent Filing)$40.19M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 17, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding49,894,130
10 Day Avg. Volume589,716
30 Day Avg. Volume657,064
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio-16.39
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$45.00Price Target Upside526.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing Phase 2 trial for CYB004 in generalized anxiety disorder presents an opportunity for future growth, with a cautiously optimistic outlook.
Financial PositionCybin raised $175 million through a registered direct financing, combined with cash of $83.8 million at the end of F2Q26, Cybin's runway extends into 2027, through multiple key data readouts.
Intellectual PropertyCYBN's products have the potential to generate stronger intellectual property positions, which are challenging to achieve with traditional psychedelic molecules.
Bears Say
Price Target ReductionThe updated model includes a reduced price target from $70 to $45, mainly due to dilution from the recent capital raise.
Share DilutionThe increased share count from the recent financing, normalization of expenses in the model, and fine-tuning the expected CYB003 and CYB004 launches resulted in a revised $55 price target from $150.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $4.81 and its highest was $10.73 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.39M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 17, 2026 which is in 57 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 13, 2025. The company reported -$1.411 earnings per share for the quarter, missing the consensus estimate of -$1.055 by -$0.357.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.59.
How many shares outstanding does Cybin have?
Cybin has 49,894,130 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -$1.411 in its last earnings report, missing expectations of -$1.055. Following the earnings report the stock price went down -8.05%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CYBN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all CYBN earnings summariesCYBN Stock 12 Month Forecast
Average Price Target
$45.00
▲(526.74% Upside)
Technical Analysis
Ownership Overview
0.45% Insiders
13.52% Other Institutional Investors
85.02% Public Companies and Individual Investors